Boston, MA 05/22/2013 (wallstreetpr) – The share prices of Unilife Corp. (NASDAQ:UNIS) had surged by 14.20 percent to close at $3.94 per share. The shares traded in the range of $3.42 to $4.26 per share during the day. Unilife Corp. (NASDAQ:UNIS) witnessed a trading volume of 4.46 million shares during the day, which was nearly three times the average trading volume of 1.61 million shares for the company.
Unilife Corp. (NASDAQ:UNIS) is involved in the development and commercial supply of injectable drug delivery systems. The company generally enters into long term collaborations with biotechnology and pharmaceutical companies to supply its differentiated drug delivery devices which would enable such companies to ensure that the clinical development, regulatory approval and lifecycle management of their injectable therapies are enhanced.
Third quarter results, 2013
The company had recently released its financial reports for the third quarter of fiscal year 2013 in which Unilife Corp. (NASDAQ:UNIS) had reported net loss of $14.1 million or $0.17 per share. Adjusted net losses after excluding non-cash share based compensation expense, depreciation and amortization expenses and interest expenses was observed to be $9.4 million or $0.12 per share. This adjusted net loss reported for third quarter of fiscal year 2013 was less than the value of $0.15 per share for the same quarter of previous year.
Unilife Corp. (NASDAQ:UNIS) is now entering into a period of hyper growth with series of agreements being signed to collaborate with pharmaceutical and bio technology companies. Such agreements are expected to generate revenues in the immediate and long term for the company.
